Literature DB >> 25444234

Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms.

Steffen Moritz1, Alexandra Hünsche2, Tania M Lincoln3.   

Abstract

Approximately 50-75% of all patients do not take their antipsychotic medication as prescribed. The current study examined reasons why patients continue versus discontinue antipsychotic medication. We were particularly interested to which extent positive attitudes towards psychotic symptoms foster medication nonadherence. An anonymous online questionnaire was set up to decrease response biases. After a strict selection process, 91 participants with schizophrenia spectrum disorders were retained for the final analyses. On average, 6.2 different reasons for nonadherence were reported. Side-effects (71.4%), sudden subjective symptom improvement (52.4%) and forgetfulness (33.3%) emerged as the most frequent reasons for drug discontinuation. Approximately one fourth of all participants (27.3%) reported at least one positive aspect of psychosis as a reason for nonadherence. In contrast, patients reported on average 3.5 different reasons for adherence (e.g., want to live a normal life (74.6%) and fear of psychotic symptoms (49.3%)). The belief that paranoia represents a survival strategy (subscale derived from the Beliefs about Paranoia Scale) was significantly associated with nonadherence. Patients' attitudes toward medication and the individual illness model need to be carefully considered when prescribing medication. In particular for patients who are likely to discontinue psychopharmacological treatment complementary or alternative psychological treatment should be sought because of a largely increased risk of relapse in the case of sudden drug discontinuation.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Adherence; Antipsychotics; Compliance; Schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25444234     DOI: 10.1016/j.euroneuro.2014.09.008

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire.

Authors:  Clifton Blackwood; Panna Sanga; Isaac Nuamah; Alexander Keenan; Arun Singh; Maju Mathews; Srihari Gopal
Journal:  Patient Prefer Adherence       Date:  2020-07-02       Impact factor: 2.711

2.  Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.

Authors:  Yoshiteru Takekita; Yosuke Koshikawa; Chiara Fabbri; Shiho Sakai; Naotaka Sunada; Ai Onohara; Keiichiro Nishida; Masafumi Yoshimura; Masaki Kato; Alessandro Serretti; Toshihiko Kinoshita
Journal:  BMC Psychiatry       Date:  2016-05-29       Impact factor: 3.630

3.  Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yuji Okuyama; Kazuto Oya; Shinji Matsunaga; Taro Kishi; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2016-12-15       Impact factor: 2.570

4.  Treatment compliance and noncompliance in psychoses.

Authors:  K Nagaraja Rao; Jitty George; C Y Sudarshan; Shamshad Begum
Journal:  Indian J Psychiatry       Date:  2017 Jan-Mar       Impact factor: 1.759

Review 5.  Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis.

Authors:  Michael Townsend; Kristin Pareja; Amy Buchanan-Hughes; Emma Worthington; David Pritchett; Malaak Brubaker; Christy Houle; Tenna Natascha Mose; Heidi Waters
Journal:  Patient Prefer Adherence       Date:  2022-02-16       Impact factor: 2.711

6.  Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness.

Authors:  Mediha Younas; Eleanor Bradley; Nikki Holmes; Dolly Sud; Ian D Maidment
Journal:  Int J Clin Pharm       Date:  2016-07-23

7.  Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling.

Authors:  John Fp Bridges; Kathleen Beusterien; Stephan Heres; Pedro Such; Joaquín Sánchez-Covisa; Anna-Greta Nylander; Elcie Chan; Anne de Jong-Laird
Journal:  Patient Prefer Adherence       Date:  2018-01-04       Impact factor: 2.711

8.  Managing information gaps on caregivers of psychotic patients in primary health settings of Yogyakarta, Indonesia.

Authors:  Carla R Marchira; Warih A Puspitosari; Ida Rochmawati; Siti Mulyani; Irwan Supriyanto
Journal:  Health Promot Perspect       Date:  2018-04-18

9.  Task-related neural mechanisms of persecutory ideation in schizophrenia and community monozygotic twin-pairs.

Authors:  Krista M Wisner; Melissa K Johnson; James N Porter; Robert F Krueger; Angus W MacDonald
Journal:  Hum Brain Mapp       Date:  2021-07-31       Impact factor: 5.038

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.